April 2010
Volume 51, Issue 13
ARVO Annual Meeting Abstract  |   April 2010
Baseline SDOCT Characteristics of AREDS2 Ancillary Study Eyes
Author Affiliations & Notes
  • J. N. Leuschen
    Duke Eye Center, Durham, North Carolina
  • K. Winter
    Duke Eye Center, Durham, North Carolina
  • M. McCall
    Duke Eye Center, Durham, North Carolina
  • T. Hwang
    Devers Eye Institute, Portland, Oregon
  • S. Srivastava
    Emory Eye Center, Atlanta, Georgia
  • W. Wong
    National Eye Institute, Bethesda, Maryland
  • T. Clemons
    EMMES Corporation, Rockville, Maryland
  • M. Harrington
    EMMES Corporation, Rockville, Maryland
  • C. Toth
    Duke Eye Center, Durham, North Carolina
  • A2A SDOCT Study Group
    Duke Eye Center, Durham, North Carolina
  • Footnotes
    Commercial Relationships  J.N. Leuschen, None; K. Winter, None; M. McCall, None; T. Hwang, None; S. Srivastava, Bausch and Lomb, C; W. Wong, None; T. Clemons, None; M. Harrington, None; C. Toth, Alcon, Genentech, C; Alcon, Genentech, R; Bioptigen, Genentech, Alcon, Sirion, F.
  • Footnotes
    Support  Genentech grant (IST-4400S), Alcon Laboratories (equipment grant), Bioptigen (equipment), and the AREDS2.
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 106. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      J. N. Leuschen, K. Winter, M. McCall, T. Hwang, S. Srivastava, W. Wong, T. Clemons, M. Harrington, C. Toth, A2A SDOCT Study Group; Baseline SDOCT Characteristics of AREDS2 Ancillary Study Eyes. Invest. Ophthalmol. Vis. Sci. 2010;51(13):106.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : There are no large population studies identifying macular characteristics of non-neovascular Age-related Macular Degeneration (AMD) using spectral domain OCT (SDOCT). Our goal is to identify the qualitative characteristics of baseline macular disease using SDOCT in eyes with non-neovascular AMD.

Methods: : We analyzed visual acuity and SDOCT data from sets of 100 scans within a 10 x 10 mm area of the macula in eyes of 316 subjects from the Age-Related Eye Disease Study 2 (AREDS2) Ancillary SDOCT Study. We included one Level 3 AMD eye from each subject in our baseline analysis. SDOCT images were graded for presence or absence of the following pathologies: vitromacular attachment (VMA), epiretinal membrane (ERM), cystoid macular edema (CME), subretinal fluid (SRF), other subretinal lesion, RPE elevation (RPEE), and RPE atrophy. Drusen were graded based on subfoveal location, reflectivity, presence of a core, serous pigment epithelial detachment (PED), and overlying intraretinal focal high reflectivity, photoreceptor thinning, and haze. Prevalence of each retinal pathology was calculated for the overall population as well as for several subcategories of participants.

Results: : The mean ETDRS baseline acuity score was 80.5 (SD 8.0). The prevalence of retinal lesions ranged from drusen found in 99.4% of study eyes to subretinal fluid in 6.7% (21 eyes). The prevalence of drusen characteristics were medium reflectivity (98.7%), haze over RPEE (94.0%), PRL thinning above RPEE (92.4%), subfoveal (88.6%), focal high reflectivity above RPEE (52.5%), high reflectivity (50.6%), low reflectivity (42.7%), core present (27.9%), and serous PED (6.7%). Subfoveal drusen were associated with a lower VA score (p= 0.027).

Conclusions: : Retinal disease in Level 3 AMD eyes can be defined qualitatively with SDOCT. VMA, PRL thinning, and some intra or subretinal fluid visible on SD OCT are not identifiable on color fundus photographs. Future studies will provide information on how these characteristics relate to risk of future disease progression.

Clinical Trial: : www.clinicaltrials.gov NCT00734487

Keywords: macula/fovea • imaging methods (CT, FA, ICG, MRI, OCT, RTA, SLO, ultrasound) • degenerations/dystrophies 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.